İrem UZUN -TDO- A final analysis of the Phase 3 trial of Pfizer's coronavirus vaccine shows it was 95% effective in preventing infections, even in older adults, and caused no serious safety concerns, the company said Wednesday. The company counted 170 cases of coronavirus infection among volunteers who took part in the trial. It said 162 infections were in people who got placebo, or plain saline shots, while eight cases were in participants who got the actual vaccine.
The results showed the vaccine to be consistently effective across people of different ages, races and ethnicities. For people above 65, the vaccine was shown to be 94 percent effective, said Pfizer. “The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,” said Pfizer chief Albert Bourla in a statement. “We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world.”
Pfizer said it expected the U.S. Food and Drug Administration's vaccine advisory committee to review and discuss the data in a public meeting that will likely be held in December. The biotechnology company Moderna, said earlier this week that an interim analysis of its late-stage study revealed its experimental vaccine appears to be 94.5% effective. The U.S. government has said it hopes Moderna and Pfizer will produce some 20 million doses for distribution in December, with the first doses offered to vulnerable people like health care workers and those with serious health conditions.